TY -的T1 -改变血液中嗜酸性粒细胞与吸入糖皮质激素治疗后可能预测长期的慢性阻塞性肺病的临床反应JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02119 -2019欧元SP - 1902119 AU Mathioudakis亚历山大·g . AU - Bikov Andras盟——Foden菲利普盟——Lahousse谎言盟——Brusselle家伙非盟-辛格,戴夫AU - Vestbo,Jørgen Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/02/20/13993003.02119 - 2019. -抽象N2 -有一个新兴角色血嗜酸性粒细胞计数(EOS)作为生物标志物指导吸入激素(ICS)治疗慢性阻塞性肺病。由于ICS给药可能影响EOS，我们假设ICS治疗后EOS的变化可能预测长期治疗的结果。伊索德的因果分析,三年,双盲试验与安慰剂比较500年µg丙酸申办751年严重慢性阻塞性肺病患者,我们评估是否最初的EOS ICS治疗期间的变化是ICS治疗反应的预测。ICS引入后1年内EOS的变化对治疗反应有很强的预测作用。抑制EOS与治疗效果相关。患者的典型,EOS抑制≥200 EOS·μL−1, ICS使用减速FEV1下降率,32毫升·年−1,恶化率减少30%。相比之下,患者经历的增加EOS≥200 EOS·μL−1, ICS使用加速FEV1下降的利率37 mLs·−1和恶化率增加80%(术中,0.0001)。在使用圣乔治呼吸问卷评估健康状况时，EOS变化不能预测临床反应。这些发现提示，ICS给药后EOS的变化可能预示着中、重度COPD患者对ICS治疗的临床反应，这些患者有加重的风险。在20%的EOS在ICS治疗后升高的患者中，ICS治疗可能与更频繁的恶化和肺功能加速下降有关。 These hypothesis-generating observations will need validation in prospectively designed studies.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Mathioudakis reports grants from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, outside the submitted work.Conflict of interest: Dr. Bikov has nothing to disclose.Conflict of interest: Philip Foden has nothing to disclose.Conflict of interest: Dr. Lahousse reports grants from AstraZeneca, grants from Chiesi, personal fees from Boehringer Ingelheim, personal fees from Novartis, outside the submitted work.Conflict of interest: Dr. Brusselle reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Teva, personal fees from Sanofi, outside the submitted work.Conflict of interest: Dr. Singh reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, grants and personal fees from GlaxoSmithKline, grants and personal fees from Glenmark, grants and personal fees from Menarini, grants and personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Peptinnovate, grants and personal fees from Pfizer, grants and personal fees from Pulmatrix, grants and personal fees from Therevance, grants and personal fees from Verona, outside the submitted work.Conflict of interest: Dr. Vestbo reports personal fees from Chiesi Pharmaceuticals, personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, outside the submitted work. ER -